MigraineScience

Global Migraine Trends Analysis

Wed, Dec 11, 24

Global Migraine Trends Analysis

A comprehensive 30-year analysis reveals that migraine affects approximately 1 in 7 people globally, with cases increasing by 58% between 1990 and 2021. While women show higher overall prevalence, men's...

Read More
Aura Characteristics in Migraine Disease

Wed, Nov 27, 24

Aura Characteristics in Migraine Disease

Understanding Migraine with Aura A study published in Cephalalgia sheds new light on migraine with aura (MwA), examining data from 272 patients across Italian headache centers. The research reveals that...

Read More
My 6 Favorite HeadaTerm 2 Features

Fri, Oct 25, 24

My 6 Favorite HeadaTerm 2 Features

HeadaTerm 2: FDA-Cleared Migraine Relief for less than $80 Use code: CEREBRALTORQUE for 20% OFF! Get HeadaTerm 2 Now Your browser does not support the video tag. Uses the same eTNS technology...

Read More
Gepant Adverse Events Chart

Thu, Aug 15, 24

Gepant Adverse Events Chart

A comprehensive analysis of real-world data has uncovered important insights into the safety profiles of gepant medications used for migraine treatment. The study, which examined adverse events reported in the...

Read More
Patent Foramen Ovale and Migraine

Mon, Jul 22, 24

Patent Foramen Ovale and Migraine

Discover the intriguing link between Patent Foramen Ovale (PFO) and migraine. Learn about new research, treatment options, and the potential impact on stroke risk. 

Read More
Migraine Attacks Independent of CGRP (cGMP-mediated migraine)

Sun, Jun 09, 24

Migraine Attacks Independent of CGRP (cGMP-mediated migraine)

A randomized, double-blind, placebo-controlled study published in Cephalalgia investigated whether sildenafil (Viagra), a phosphodiesterase-5 (PDE-5) inhibitor that increases cGMP levels, could induce migraine attacks in individuals with migraine who were pre-treated with...

Read More